In contrast to statements made in the above paper, measurements of waist and hip circumference were in fact available. Table 2 (Biochemistry and anthropometric measurements at baseline and study end) and Table 3 (Treatment differences in change for blood and anthropometric measurements in the intention-to-treat analysis) are updated here to include the missing data for waist circumference, hip circumference and waist/hip ratio. Analysis of the data did not show any significant effects of the full-dose nut diet, full-dose muffin diet or the half-dose nut diet on waist circumference, hip circumference or waist/hip ratio within groups or between groups. (227) 475 (438) 392 (215) 496 (368) 404 ( For baseline: HbA 1c , glucose and blood pressure baseline values were calculated as the mean of values at screening and weeks −1 and 0; for weight, BMI, waist circumference, hip circumference, waist/hip ratio and antioxidants, values at week 0 were used; for lipids, lipoproteins and CRP, the mean of weeks −1 and 0 were used (n = 93), or screening and week 0 if week −1 was missing (n = 17). For n = 6, only week 0 data were available. Data were not available for n = 1 who was randomised to the half-dose nut group but dropped out prior to week 0; for particle size and clotting factors, week 0 was used (n = 113) or week −1 if week 0 had insufficient serum quantities or samples were missing (n = 4) For study end: HbA 1c , glucose and blood pressure study end values were calculated as the mean of weeks 8, 10 and 12 (final month); for lipid, lipoproteins and CRP, week 8, 10 and 12 samples were also used apart from for n = 3 who only had week 8 samples available; for weight, BMI, waist circumference, hip circumference and waist/hip ratio, week 12 values were used (n = 100) or, if not available, week 8 values (n = 3); for particle size and clotting factors, owing to limited sample availability, week 12 samples were used (n = 97) or, if not available, week 10 samples (n = 3), or week 8 samples (n = 3; where week 10 samples were also unavailable); for antioxidants, week 12 samples were used where serum samples were available (conjugates dienes and TBARS, n = 100; protein thiols, n = 99 [analytical failure lead to loss of data for n = 1 sample]) e n = 100 (full-dose nut group, n = 38; half-dose nut group, n = 32; full-dose muffin group, n = 30) f n = 99 (full-dose nut group, n = 38; half-dose nut group, n = 31; full-dose muffin group, n = 30); loss of n = 1 data point due to analytical failure for one participant in the half-dose nut group Adj, adjusted; TBARS, thiobarbituric acid reactive substances
